KFAS
PCRX icon

Keating Financial Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Keating Financial Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Sell
4,331
-438
-9% -$10.4K 0.01% 465
2026
Q1 		$108K Sell
4,769
-66,574
-93% -$1.48M 0.02% 445
2025
Q4 		$1.85M Buy
+71,343
New +$1.7M 0.25% 68

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's PCRX Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Pacira BioSciences (PCRX) stake by 9.2% in Q2 2026, selling an estimated $10.4K and leaving 4,331 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #465.

Keating Financial Advisory Services first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.85M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Keating Financial Advisory Services held 4,331 shares of Pacira BioSciences worth $110K as of Q2 2026.
  • Keating Financial Advisory Services sold 438 Pacira BioSciences shares in Q2 2026, an estimated $10.4K.
  • Pacira BioSciences made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #465 holding.
  • Keating Financial Advisory Services first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Pacira BioSciences position peaked at $1.85M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.